Summary
The metabolism of encainide occurs in the liver and is polymorphically distributed according to the same genetic factor that determines the 4-hydroxylation of debrisoquine. Over 90% of patients are extensive metabolizers (EM) in whom the oral bioavailability of encainide is only 30% because of extensive first-pass metabolism. In EMs, elimination t1/2 is about 2.5 hours, with a systemic clearance of 1.8 l/min. The plasma concentrations of the major metabolites O-desmethyl-encainide (ODE) and 3-methoxy-O-desmethyl-encainide (3-MODE) are higher than those of encainide and have antiarrhythmic activity. The remaining patients (<10%) are poor metabolizers (PM), in whom the oral bioavailability is near 88% with an elimination t1/2 of 8–11 hours and a systemic clearance of 0.2 l/min. Encainide plasma concentrations are 10- to 20-fold higher than in EMs, but considerably less ODE and no 3-MODE is formed by the PMs. The conversion to the N-desmethyl-encainide (NDE) metabolite seems to be similar in both metabolizer groups, and plasma protein binding of encainide of 70–78% is also similar.
During long-term treatment, the antiarrhythmic metabolites of encainide accumulate in the plasma, so that the relationships between the effect and plasma concentration on encainide, ODE, and 3-MODE are not always obvious. Minimally effective plama concentrations appear to be approximately 300 ng/ml of encainide, 35 ng/ml of ODE, and 100 ng/ml of 3-MODE.
Dose adjustment is necessary in patients with decreased kidney function, but not in patients with cirrhosis, in whom the plasma levels of metabolites appear to be comparable to those in normal subjects.
Similar content being viewed by others
References
Roden DM, Reele SB, Higgins SB, et al. Total suppression of ventricular arrhythmias by encainide: Pharmacokinetics and electrocardiographic characteristics. N Engl J Med 1980;302:877–882.
Woosley RL, Roden DM, Dai G, et al. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther 1986;39:282–287.
Wang T, Roden DM, Wollfenden HT, et al. Influence of genetic polymorphism on the disposition of encainide in man. J Pharmac Exper Ther 1984;228:605–611.
Kates RE, Harrison DC, Winkle RA. Metabolite cumulation during long-term oral encainide administration. Clin Pharmacol Ther 1982;31:427–432.
Roden DM, Wood AJJ, Wilkinson GR, Woosley RL. Disposition kinetics of encainide and metabolites. Am J Cardiol 1986;58:4C-9C.
Quart BD, Gallo GD, Sami MH, Wood AJJ. Drug interaction studies and encainide use in renal and hepatic impairment. Am J Cardol 1986;58:104C-113C.
Latini R, Gillis AM, Kates RE. Myocardial uptake of encainide and its two major metabolites, O-demethyl-encainide and 3-methoxy-O-demethyl-encainide in the dog. J Cardiovasc Pharmacol 1984;6:663–667.
Winkle RA, Peters F, Kates RE, Harrison DC. Possible contribution of encainide metabolites to the long-term anti-arrhythmic efficacy of encainide. Am J Cardiol 1983;51: 1182–1188.
Carey EL, Duff HJ, Roden DM, et al. Encainide and its metabolites: Comparative effects in man on ventricular arrhythmias and electrocardiographic intervals. J Clin Invest 1984;73:539–547.
Barby JT, Chaffin PL, Rigby S, et al. Pharmacology of encainide metabolites in man (abstract). Circulation 1985;72 (Suppl III):170.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jaillon, P. Pharmacokinetics and metabolism of encainide. Cardiovascular Drugs and Therapy 4 (Suppl 3), 561–565 (1990). https://doi.org/10.1007/BF00357031
Issue Date:
DOI: https://doi.org/10.1007/BF00357031